tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2020 Aug 19;1-29.
doi: 10.1080/22221751.2020.1812436. Online ahead of print.
Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice
Yuan Yin[SUP] 1 2 [/SUP], BeiBei Li[SUP] 2 [/SUP], Linting Zhou[SUP] 2 [/SUP], Jian Luo[SUP] 2 [/SUP], Xueying Liu[SUP] 2 [/SUP], Shilei Wang[SUP] 2 [/SUP], Qun Lu[SUP] 1 [/SUP], Wensong Tan[SUP] 3 [/SUP], Ze Chen[SUP] 2 4 [/SUP]
Affiliations
Abstract
The nucleoprotein (NP) is a highly conserved internal protein of the influenza virus, a major target for universal influenza vaccine. Our previous studies have proven NP-based subunit vaccine can provide partial protection in mice. It is reported that the protein transduction domain (PTD) TAT protein from human immunodeficiency virus-1 (HIV-1) is able to penetrate cells when added exogenous protein and could effectively enhance the immune response induced by the exogenous protein. In present study, the recombinant protein TAT-NP, a fusion of TAT and NP was effectively expressed in Escherichia coli and purified as a candidate component for an influenza vaccine. We evaluated the immunogenicity and protective efficacy of recombinant influenza TAT-NP vaccine by intranasal immunization. In vitro experiments showed that TAT-NP could efficiently penetrate into cells. Animal results showed that mice vaccinated with TAT-NP could not only induce higher levels of IgG and mucosal IgA, but also elicit a robust cellular immune response. Moreover, the TAT-NP fusion protein could significantly increase the protection of mice against lethal doses of homologous influenza virus PR8 and could also provide mice protection against a lethal dose challenge against heterosubtypic H9N2 and H3N2 influenza virus. In conclusion, the recombinant TAT-NP might be a universal vaccine candidate against influenza virus.
Keywords: Influenza virus; Nucleoprotein; Protein transduction domain; Universal vaccine.
. 2020 Aug 19;1-29.
doi: 10.1080/22221751.2020.1812436. Online ahead of print.
Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice
Yuan Yin[SUP] 1 2 [/SUP], BeiBei Li[SUP] 2 [/SUP], Linting Zhou[SUP] 2 [/SUP], Jian Luo[SUP] 2 [/SUP], Xueying Liu[SUP] 2 [/SUP], Shilei Wang[SUP] 2 [/SUP], Qun Lu[SUP] 1 [/SUP], Wensong Tan[SUP] 3 [/SUP], Ze Chen[SUP] 2 4 [/SUP]
Affiliations
- PMID: 32811334
- DOI: 10.1080/22221751.2020.1812436
Abstract
The nucleoprotein (NP) is a highly conserved internal protein of the influenza virus, a major target for universal influenza vaccine. Our previous studies have proven NP-based subunit vaccine can provide partial protection in mice. It is reported that the protein transduction domain (PTD) TAT protein from human immunodeficiency virus-1 (HIV-1) is able to penetrate cells when added exogenous protein and could effectively enhance the immune response induced by the exogenous protein. In present study, the recombinant protein TAT-NP, a fusion of TAT and NP was effectively expressed in Escherichia coli and purified as a candidate component for an influenza vaccine. We evaluated the immunogenicity and protective efficacy of recombinant influenza TAT-NP vaccine by intranasal immunization. In vitro experiments showed that TAT-NP could efficiently penetrate into cells. Animal results showed that mice vaccinated with TAT-NP could not only induce higher levels of IgG and mucosal IgA, but also elicit a robust cellular immune response. Moreover, the TAT-NP fusion protein could significantly increase the protection of mice against lethal doses of homologous influenza virus PR8 and could also provide mice protection against a lethal dose challenge against heterosubtypic H9N2 and H3N2 influenza virus. In conclusion, the recombinant TAT-NP might be a universal vaccine candidate against influenza virus.
Keywords: Influenza virus; Nucleoprotein; Protein transduction domain; Universal vaccine.